These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 8531323

  • 41. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
    [Abstract] [Full Text] [Related]

  • 42. [Successful therapy of Ph1 positive chronic myelocytic leukemia with oral form of etoposide].
    Aihara M, Sasaki Y, Yoshida Y.
    Rinsho Ketsueki; 1990 Oct; 31(10):1745-9. PubMed ID: 2255067
    [Abstract] [Full Text] [Related]

  • 43. [Hematologic response to low dose natural interferon-alpha in a case of CML with myelo-megakaryoblastic crisis].
    Nozaki H, Usui T, Yamauchi K, Kobayashi N, Nakamura Y, Watanabe K, Nagao T, Arimori S.
    Rinsho Ketsueki; 1993 Feb; 34(2):232-4. PubMed ID: 8492424
    [Abstract] [Full Text] [Related]

  • 44. [Thrombocytosis in chronic myelogenous leukemia (CML) controlled by interferon alpha (IFN-alpha)].
    Koike G, Otsuka T, Shibuya T, Niho Y.
    Rinsho Ketsueki; 1989 Mar; 30(3):400-3. PubMed ID: 2769964
    [Abstract] [Full Text] [Related]

  • 45. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M.
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [Abstract] [Full Text] [Related]

  • 46. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha.
    Michallet M, Thiébaut A, Philip I, Charrin C, Vigouroux C, Thomas X, Bilger K, Belhabri A, Guyotat D, Corront B, Salles B, Dumontet C, Péaud PY, Vilque JP, Devidas A, Fière D.
    Leukemia; 2000 Dec; 14(12):2064-9. PubMed ID: 11187894
    [Abstract] [Full Text] [Related]

  • 47. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M.
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [Abstract] [Full Text] [Related]

  • 48. [Chronic myelocytic leukemia induced into remission by interferon-alpha associated with early esophageal cancer].
    Annoh S, Umeda M, Arai N, Shikoshi K, Su CY, Yasushi T, Kitazawa Y, Shirai T.
    Rinsho Ketsueki; 1991 Jul; 32(7):786-90. PubMed ID: 1920843
    [Abstract] [Full Text] [Related]

  • 49. An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia.
    Whiteway AJ, Reid CD, Cross NC.
    Leukemia; 1997 Apr; 11(4):614-6. PubMed ID: 9096705
    [Abstract] [Full Text] [Related]

  • 50. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
    Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K.
    Blood; 1995 Aug 01; 86(3):906-16. PubMed ID: 7620184
    [Abstract] [Full Text] [Related]

  • 51. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
    Armenta D, Espallargas C, Paz A, Rodríguez Martorel J, Ladines R, Alvarez C, Román J, Andrés P.
    Sangre (Barc); 1996 Dec 01; 41(6):465-7. PubMed ID: 9148424
    [Abstract] [Full Text] [Related]

  • 52. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Maloisel F, Uettwiller F, Laplace A, Lioure B, Herbrecht R, Mark M, Dufour P.
    Cancer Genet Cytogenet; 1999 Sep 01; 113(2):172-6. PubMed ID: 10484986
    [Abstract] [Full Text] [Related]

  • 53. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
    Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU.
    Ann Intern Med; 1991 Apr 01; 114(7):532-8. PubMed ID: 2001086
    [Abstract] [Full Text] [Related]

  • 54. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE, Messner H.
    Br J Cancer; 1990 Jun 01; 61(6):895-8. PubMed ID: 2372493
    [Abstract] [Full Text] [Related]

  • 55. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
    Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H.
    Blut; 1989 Jun 01; 58(6):275-8. PubMed ID: 2736308
    [Abstract] [Full Text] [Related]

  • 56. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
    Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H.
    Br J Haematol; 1989 Jul 01; 72(3):350-6. PubMed ID: 2765403
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. [Ranimustine].
    Masaoka T.
    Gan To Kagaku Ryoho; 1990 Feb 01; 17(2):301-7. PubMed ID: 2405779
    [Abstract] [Full Text] [Related]

  • 59. Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia.
    Dow LW, Raimondi SC, Culbert SJ, Ochs J, Kennedy W, Pinkel DP.
    Cancer; 1991 Oct 15; 68(8):1678-84. PubMed ID: 1833044
    [Abstract] [Full Text] [Related]

  • 60. Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.
    Fiegl M, Mitterbauer G, Weltermann A, Pirc-Danoewinata H, Jäger U.
    Leuk Lymphoma; 1999 Oct 15; 35(3-4):409-13. PubMed ID: 10706467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.